Khurram Jamil - 17 Dec 2025 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
Chief Medical Officer
Signature
Jack W. Callicutt, by power of attorney
Issuer symbol
GALT
Transactions as of
17 Dec 2025
Net transactions value
-$101,403
Form type
4
Filing time
19 Dec 2025, 16:06:14 UTC
Previous filing
14 Nov 2025
Next filing
05 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jamil Khurram Chief Medical Officer 4960 PEACHTREE INDUSTRIAL BLVD, SUITE 240, NORCROSS Jack W. Callicutt, by power of attorney 19 Dec 2025 0002032345

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GALT Common Stock Sale $31,532 -4,479 -100% $7.04 0 17 Dec 2025 Direct F1, F2
transaction GALT Common Stock Options Exercise $14,219 +6,463 $2.20 6,463 17 Dec 2025 Direct F1
transaction GALT Common Stock Sale $45,500 -6,463 -100% $7.04 0 17 Dec 2025 Direct F1, F2
transaction GALT Common Stock Options Exercise $21,250 +8,500 $2.50 8,500 17 Dec 2025 Direct F1
transaction GALT Common Stock Sale $59,840 -8,500 -100% $7.04 0 17 Dec 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock option (right to buy) Options Exercise $0 -6,463 -6% $0.000000 102,037 17 Dec 2025 Common Stock 6,364 $2.20 Direct F1, F3
transaction GALT Stock option (right to buy) Options Exercise $0 -8,500 -15% $0.000000 50,000 17 Dec 2025 Common Stock 8,500 $2.50 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on July 15, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on November 14, 2025.
F2 The shares were sold in multiple transactions at prices ranging from $7.00 to $7.11. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
F3 The options vest as follows: 50,000 on March 11, 2025, with 50,000 scheduled to vest on each of March 11, 2026 and March 11, 2027.
F4 The options vest as follows: 25,000 on each of October 31, 2024, January 31, 2025, April 30, 2025, and July 31, 2025.